Cicala Carlo M, Bauer Sebastian, Heinrich Michael C, Serrano César
Sarcoma Translational Research Group, Vall d'Hebron Institute of Oncology (VHIO), Carrer de Natzaret 115-117, 08035 Barcelona, Spain.
Department of Medical Oncology and Sarcoma Center, West German Cancer Center, and DKTK partner site Essen, German Cancer Consortium (DKTK), University Duisburg-Essen, Medical School, Hufelandstraße 55, Essen 45122, Germany.
Hematol Oncol Clin North Am. 2025 Aug;39(4):773-784. doi: 10.1016/j.hoc.2025.04.006. Epub 2025 May 13.
This review discusses the current and future landscape of advanced gastrointestinal stromal tumor (GIST) treatment. It covers the role of tyrosine kinase inhibitors (TKIs), specifically imatinib, and further treatment options, such as sunitinib, regorafenib, and ripretinib, as well as avapritinib for platelet-derived growth factor receptor alpha D842V mutations. In addition, this review emphasizes individualized treatment strategies within multidisciplinary expert teams, including surgery and other locoregional therapies, together with the importance of mutation-guided approaches, particularly for wild-type GISTs. Finally, it explores the potential of next-generation KIT inhibitors, combination therapies, and other investigational approaches.
本综述讨论了晚期胃肠道间质瘤（GIST）治疗的现状和未来前景。它涵盖了酪氨酸激酶抑制剂（TKIs）的作用，特别是伊马替尼，以及其他治疗选择，如舒尼替尼、瑞戈非尼和瑞派替尼，还有用于血小板衍生生长因子受体α D842V突变的阿伐替尼。此外，本综述强调了多学科专家团队中的个体化治疗策略，包括手术和其他局部区域治疗，以及突变指导方法的重要性，特别是对于野生型GIST。最后，它探讨了下一代KIT抑制剂、联合疗法和其他研究方法的潜力。
